NBPNovaBridge Biosciencesvs its industry peers
A metric-by-metric comparison of NovaBridge Biosciences against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NBPThis | $415M#2 | — | 1.8x#1 | 657.1x#3 | — | -108.1%#4 | -14916.0%#3 | -20.0%#2 | -384.3%#2 | — | -59.5%#2 | — |
| MENS | $163M#4 | — | — | — | — | -54.7%#3 | — | — | — | — | -96.3%#4 | — |
| MREO | $250M#3 | — | 8.7x#3 | 499.0x#2 | — | -3.2%#2 | -8021.4%#2 | 146.2%#1 | — | — | -83.2%#3 | — |
| MRVI | $1.1B#1 | — | 5.2x#2 | 5.8x#1 | -28.3%#1 | 9.7%#1 | -115.9%#1 | -63.9%#3 | -76.4%#1 | — | 163.9%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-22.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice